Global to push GA events into
skip to main content

Title: Use of glycolytic pathways for inhibiting or measuring oncogenic signaling

Disclosed are methods in which glucose metabolism is correlated to oncogenesis through certain specific pathways; inhibition of certain enzymes is shown to interfere with oncogenic signaling, and measurement of certain enzyme levels is correlated with patient survival. The present methods comprise measuring level of expression of at least one of the enzymes involved in glucose uptake or metabolism, wherein increased expression of the at least one of the enzymes relative to expression in a normal cell correlates with poor prognosis of disease in a patient. Preferably the genes whose expression level is measured include GLUT3, PFKP, GAPDH, ALDOC, LDHA and GFPT2. Also disclosed are embodiments directed towards downregulating the expression of some genes in glucose uptake and metabolism.
Inventors:
;
Issue Date:
OSTI Identifier:
1366731
Assignee:
The Regents of the University of California LBNL
Patent Number(s):
9,689,042
Application Number:
14/020,361
Contract Number:
AC02-05CH11231
Resource Relation:
Patent File Date: 2013 Sep 06
Research Org:
Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
Sponsoring Org:
USDOE
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES

Works referenced in this record:

The cAMP-Epac-Rap1 Pathway Regulates Cell Spreading and Cell Adhesion to Laminin-5 through the α3β1 Integrin but Not the α6β4 Integrin
journal, August 2004
  • Enserink, Jorrit M.; Price, Leo S.; Methi, Trond
  • Journal of Biological Chemistry, Vol. 279, Issue 43, p. 44889-44896
  • DOI: 10.1074/jbc.M404599200